Back To Education Zone

touchCONGRESS Expert Interviews

HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?

Menu

Introduction

Watch a series of internationally renowned clinical specialists from Europe and the United States discuss key clinical data of interest from the European Society for Medical Oncology (ESMO) Breast Cancer Congress, Berlin, Germany, 2–4 May 2019.

The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After watching these touchCONGRESS Expert Interviews from ESMO 2019, you should be able to:

  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognise the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Please feedback on this touchCONGRESS Expert Interviews on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).